Stocks of ADMA Biologics Inc. (NASDAQ:ADMA) traded higher last session on Wall Street, down -2.23% to $3.94.
According to the data, ADMA Biologics Inc. (NASDAQ:ADMA) has 4 analysts covering its stock. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $4.50, we find $5.00. Given the previous closing price of $4.03, this indicates a potential upside of 24.07 percent. ADMA stock price is now 13.98% away from the 50-day moving average and 23.64% away from the 200-day moving average. The market capitalization of the company currently stands at $862.94M.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
A total of 0 analysts have issued a hold rating and 4 have given it a buy rating. Brokers who have rated the stock have averaged $5.13 as their price target over the next twelve months.
In other news, Grossman Adam S, President and CEO bought 14,983 shares of the company’s stock on Dec 09. The stock was bought for $42,851 at an average price of $2.86. Upon completion of the transaction, the President and CEO now directly owns 2,203,708 shares in the company, valued at $8.68 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 09, President and CEO Grossman Adam S bought 14,982 shares of the business’s stock. A total of $42,849 was incurred on buying the stock at an average price of $2.86. This leaves the insider owning 1,143,426 shares of the company worth $4.51 million. Insiders disposed of 570,399 shares of company stock worth roughly $2.25 million over the past 1 year. A total of 1.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ADMA stock. A new stake in ADMA Biologics Inc. shares was purchased by NORGES BANK during the first quarter worth $7,066,000. AMERICAN CENTURY COMPANIES INC invested $4,394,000 in shares of ADMA during the first quarter. In the first quarter, GLOBEFLEX CAPITAL L P acquired a new stake in ADMA Biologics Inc. valued at approximately $931,000. HILLSDALE INVESTMENT MANAGEMENT INC. acquired a new stake in ADMA for approximately $810,000. PROFUND ADVISORS LLC purchased a new stake in ADMA valued at around $719,000 in the second quarter. In total, there are 231 active investors with 67.30% ownership of the company’s stock.
Thursday’s opening bell rang with an opening price of $4.0000 for ADMA Biologics Inc. (NASDAQ: ADMA). During the past 12 months, ADMA Biologics Inc. has had a low of $1.84 and a high of $4.30. As of last week, the company has a debt-to-equity ratio of 0.99, a current ratio of 7.20, and a quick ratio of 2.70. The fifty day moving average price for ADMA is $3.4728 and a two-hundred day moving average price translates $3.1963 for the stock.
The latest earnings results from ADMA Biologics Inc. (NASDAQ: ADMA) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.03, beating analysts’ expectations of -$0.04 by 0.01. This compares to -$0.13 EPS in the same period last year. The net profit margin was -26.20% and return on equity was -37.20% for ADMA. The company reported revenue of $56.91 million for the quarter, compared to $29.1 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 95.56 percent. For the current quarter, analysts expect ADMA to generate $56.45M in revenue.
ADMA Biologics Inc.(ADMA) Company Profile
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Leave a Reply